Cadence Pharmaceuticals Inc

Cadence Pharmaceuticals — Investor Presentation (February 2008)

25 slides from Cadence Pharmaceuticals's investor presentation, Feb 4, 2008

  1. Slide 1: Corporate Overview February 2008

    Corporate Overview February 2008 Improving the lives of hospitalized patients

  2. Slide 2: Ted Schroeder, President, CEO & co-founder

    Ted Schroeder President, CEO & co-founder

  3. Slide 3: Forward-looking statements

    Forward-looking statements This presentation contains forward-looking statements, including statements regarding: the timeframes in which we expect to complete and disclose results from our clinical trials; the timeframes in which we expect to file submissions to regulatory authorities seeking marke

  4. Slide 4: Hospital-focused business strategy

    Hospital-focused business strategy Acquire, develop and commercialize late stage products Target $50+ billion US hospital market with focused sales force AcetavanceTM - Phase III for acute pain and fever (US) Market leading injectable analgesic in EU - BMS '07 sales ~80 million units Opioid sparing

  5. Slide 5: Acetavance intravenous acetaminophen

    AcetavanceTM intravenous acetaminophen

  6. Slide 6: Acetavance: product overview

    AcetavanceTM: product overview Oral acetaminophen - most widely used drug for pain and fever Available in US for 50+ years Active ingredient in Tylenol(r) and 300+ medications Acetavance - proprietary IV formulation Marketed by BMS in Europe since 2002 (PerfalganTM) Cadence acquired US and Canadian

  7. Slide 7: Acetavance: limitations of current IV therapies

    AcetavanceTM: limitations of current IV therapies Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Opioids NSAIDs Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs t

  8. Slide 8: Acetavance: foundation of multi-modal analgesia

    AcetavanceTM: foundation of multi-modal analgesia 1 Sinatra, et al. Anesthesiology. April 2005 IV acetaminophen + opioids IV acetaminophen +/- opioids IV acetaminophen First analgesic drug post-op Add opioids if pain increases Result1: >33% decrease in opioids Superior pain relief Better patient sat

  9. Slide 9: Acetavance: EU market leader

    AcetavanceTM: EU market leader unit sales (million) product sales (USD million) 80 67 56 45 28 $11 $60 $112 $140 $167 $200 2002 2003 2004 2005 2006 2007e European IV Acetaminophen Sales EU market share leader: 21% share of all injectable analgesics (1H07) $2.50 average price/unit - $7-9 in select Eu

  10. Slide 10: Acetavance: large US market opportunity

    Market Size Pricing Share AcetavanceTM: large US market opportunity 278 million IV analgesic units1 (2006) Acetavance expected to grow market $7/vial Toradol(r) US price in 1997 Upper limit of pricing to be tested EU: 21% of all IV analgesic units Upside potential Significant product opportunity Sal

  11. Slide 11: Acetavance: abdominal GYN surgery (301) results

    AcetavanceTM: abdominal GYN surgery (301) results Treatment of pain following abdominal gynecologic surgery Acetavance vs. placebo over 48 hours Primary endpoint (SPI-24/48hrs) not statistically significant Huge standard deviation in pain scores immediately post-op Positive secondary endpoints: Pain

  12. Slide 12: Acetavance: demonstrated safety and efficacy

    AcetavanceTM: demonstrated safety and efficacy ?2,000 subjects received IV acetaminophen in clinical trials Safety consistent with oral acetaminophen 48 hour safety first established in Cadence 301 study Adverse events equal or slightly below placebo Safety Efficacy 10 successful, randomized, placeb

  13. Slide 13: Acetavance: 505(b)2 path to NDA

    Study Status BMS-9805IC-CIS (Dietlin) Complete CADX 101 Complete CADX 302 Complete BMS-RC-201-3002 (Sinatra) Complete CADX 301 Complete CADX 102 Ongoing CADX 304 Ongoing CADX 351 1Q08 initiation CADX 352 1Q08 initiation Requirement TBD with FDA Requirement Single dose PK Multiple dose PK - adults Si

  14. Slide 14: IV Acetaminophen: strong intellectual property

    R* IV Acetaminophen: strong intellectual property Acetaminophen in solution Acetaminophen polymers Free radical formation + Formulation must protect acetaminophen from O2 degradation Covers process for removing oxygen from a solution and solutions made by that process Expires in 2021 Issued US proce

  15. Slide 15: Omigard omiganan 1% aqueous gel

    OmigardTM omiganan 1% aqueous gel

  16. Slide 16: Omigard: product overview

    OmigardTM: product overview Topical antimicrobial for catheter-related infections Bactericidal and fungicidal Rapid and prolonged effect Powerful resistance profile Excellent safety profile Convenient application Composition of matter to 2017 plus extensions Cadence acquired North American and Europ

  17. Slide 17: Omigard: significant unmet need

    OmigardTM: significant unmet need Catheters are leading cause of BSI 325,000 catheter-related BSIs 40,000 - 80,000 deaths Mounting pressures to lower infection rates Mandatory hospital reporting Changes in CMS reimbursement $25,000 per infection Significant limitations with current standard of care

  18. Slide 18: Omigard: large market opportunity

    OmigardTM: large market opportunity 20 million central lines placed in US 11 million CVCs 7 million arterial lines 2 million PICCs 9% CAGR 3 to 4 applications of Omigard per catheter Dressing change and reapplication every 3 days >50 million potential applications of Omigard in US

  19. Slide 19: Omigard: clear path to FDA approval

    OmigardTM: clear path to FDA approval Special Protocol Assessment (SPA) completed with FDA Single confirmatory Phase III trial required for approval Primary endpoint: Local Catheter Site Infection (LCSI) 42% LCSI reduction (p=0.03) demonstrated in previous Phase III study (n=1,407) Phase III CLIRS t

  20. Slide 20: Omigard: perceived as major advancement

    OmigardTM: perceived as major advancement Harris Interactive, Inc. November 2006 85% Combined Extremely Favorable/Very Favorable Impression Physicians (n=230) Nurses (n=75) Pharmacists (n=41)

  21. Slide 21: Cadence: key milestones

    Acetavance "speed of onset" fever trial results 1Q08 Acetavance FDA meeting 2Q08 Acetavance Phase III laparoscopic surgery results 2H08 Omigard Phase III CLIRS results 2H08 Acetavance NDA submission 1H09* Omigard NDA submission 1H09 Cadence: key milestones * Subject to discussions with FDA

  22. Slide 22: Cadence: experienced management team

    Individual/Title Select Previous Affiliations Ted Schroeder BMS, Dura, Elan President, CEO & co-founder Jim Breitmeyer, MD, PhD Serono, AME, Lilly EVP, Development & Chief Medical Officer Hazel Aker, JD Alaris, CancerVax, Ambrx SVP, General Counsel Bill Craig, PhD Telios, Alpha, ISTA SVP, Pharmaceut

  23. Slide 23: Cadence: financial position

    Nine months ended September 30, 2007: Operating expenses $39.6 million Shares outstanding 29.1 million As of December 31, 2007: Cash and cash equivalents $56 million Cadence: financial position

  24. Slide 24: Cadence: highlights

    Hospital-focused business strategy Acquire, develop and commercialize late stage products Target $50+ billion US hospital market with focused sales force AcetavanceTM - Phase III for acute pain and fever (US) Market leading injectable analgesic in EU - BMS '07 sales ~80 million units Opioid sparing

  25. Slide 25: Improving the lives of hospitalized patients

    NASDAQ: CADX Improving the lives of hospitalized patients

Cadence Pharmaceuticals — Investor Presentation (February 2008) on 6ix